» Articles » PMID: 38705513

Amino Acid Transporters Within the Solute Carrier Superfamily: Underappreciated Proteins and Novel Opportunities for Cancer Therapy

Overview
Journal Mol Metab
Specialty Cell Biology
Date 2024 May 5
PMID 38705513
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Solute carrier (SLC) transporters, a diverse family of membrane proteins, are instrumental in orchestrating the intake and efflux of nutrients including amino acids, vitamins, ions, nutrients, etc, across cell membranes. This dynamic process is critical for sustaining the metabolic demands of cancer cells, promoting their survival, proliferation, and adaptation to the tumor microenvironment (TME). Amino acids are fundamental building blocks of cells and play essential roles in protein synthesis, nutrient sensing, and oncogenic signaling pathways. As key transporters of amino acids, SLCs have emerged as crucial players in maintaining cellular amino acid homeostasis, and their dysregulation is implicated in various cancer types. Thus, understanding the intricate connections between amino acids, SLCs, and cancer is pivotal for unraveling novel therapeutic targets and strategies.

Scope Of Review: In this review, we delve into the significant impact of amino acid carriers of the SLCs family on the growth and progression of cancer and explore the current state of knowledge in this field, shedding light on the molecular mechanisms that underlie these relationships and highlighting potential avenues for future research and clinical interventions.

Major Conclusions: Amino acids transportation by SLCs plays a critical role in tumor progression. However, some studies revealed the tumor suppressor function of SLCs. Although several studies evaluated the function of SLC7A11 and SLC1A5, the role of some SLC proteins in cancer is not studied well. To exert their functions, SLCs mediate metabolic rewiring, regulate the maintenance of redox balance, affect main oncogenic pathways, regulate amino acids bioavailability within the TME, and alter the sensitivity of cancer cells to therapeutics. However, different therapeutic methods that prevent the function of SLCs were able to inhibit tumor progression. This comprehensive review provides insights into a rapidly evolving area of cancer biology by focusing on amino acids and their transporters within the SLC superfamily.

Citing Articles

Roles and therapeutic potential of the SLC family in prostate cancer-literature review.

Fu Y, Chen J, Zhu X, Ding M, Wang H, Fu S BMC Urol. 2025; 25(1):32.

PMID: 39966814 PMC: 11837367. DOI: 10.1186/s12894-025-01714-w.


A Review on the Role of Human Solute Carriers Transporters in Cancer.

Hossen M, Islam M, Yasin M, Ibrahim M, Das A Health Sci Rep. 2025; 8(1):e70343.

PMID: 39807482 PMC: 11725534. DOI: 10.1002/hsr2.70343.


Role of solute carrier transporters in ovarian cancer (Review).

Quaresima B, Scicchitano S, Faniello M, Mesuraca M Int J Mol Med. 2024; 55(2).

PMID: 39611477 PMC: 11637498. DOI: 10.3892/ijmm.2024.5465.


Hydrolyzed protein formula improves the nutritional tolerance by increasing intestinal development and altering cecal microbiota in low-birth-weight piglets.

Bai M, Liu H, Yan Y, Duan S, Szeto I, He J Front Nutr. 2024; 11:1439110.

PMID: 39555191 PMC: 11565607. DOI: 10.3389/fnut.2024.1439110.


The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Head and Neck Squamous Cell Carcinoma.

Cho S, Kang N Cancers (Basel). 2024; 16(18).

PMID: 39335197 PMC: 11430461. DOI: 10.3390/cancers16183226.


References
1.
Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J . Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11. Cancer Res. 2021; 81(20):5217-5229. PMC: 8530936. DOI: 10.1158/0008-5472.CAN-21-0567. View

2.
Meixner E, Goldmann U, Sedlyarov V, Scorzoni S, Rebsamen M, Girardi E . A substrate-based ontology for human solute carriers. Mol Syst Biol. 2020; 16(7):e9652. PMC: 7374931. DOI: 10.15252/msb.20209652. View

3.
Shen L, Zhang J, Zheng Z, Yang F, Liu S, Wu Y . PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. Int J Biol Sci. 2022; 18(14):5459-5474. PMC: 9461664. DOI: 10.7150/ijbs.74546. View

4.
Missiaen R, Anderson N, Kim L, Nance B, Burrows M, Skuli N . GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022; 34(8):1151-1167.e7. PMC: 9357184. DOI: 10.1016/j.cmet.2022.06.010. View

5.
Schumann T, Konig J, Henke C, Willmes D, Bornstein S, Jordan J . Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacol Rev. 2019; 72(1):343-379. DOI: 10.1124/pr.118.015735. View